Madison Wealth Partners Inc Buys Shares of 5,291 Danaher Corporation $DHR

Madison Wealth Partners Inc bought a new stake in shares of Danaher Corporation (NYSE:DHR) during the second quarter, HoldingsChannel.com reports. The fund bought 5,291 shares of the conglomerate’s stock, valued at approximately $1,008,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. BlackRock Inc. bought a new position in Danaher in the 2nd quarter valued at $10,492,520,000. State Street Corp increased its stake in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after purchasing an additional 472,608 shares during the period. Capital International Investors lifted its position in shares of Danaher by 8.9% during the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after purchasing an additional 1,334,221 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

NYSE DHR opened at $219.42 on Friday. The company has a market cap of $154.25 billion, a PE ratio of 38.97, a P/E/G ratio of 2.72 and a beta of 0.78. The firm’s 50 day moving average price is $195.80 and its 200-day moving average price is $192.61. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. Sell-side analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. TD Cowen reduced their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Citigroup began coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price on the stock. DZ Bank initiated coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 target price on the stock. Guggenheim lowered their price target on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Finally, Royal Bank Of Canada increased their price objective on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.